• Wednesday, April 8, 2020 @ 12:00 am

  • Robust cash position at December 31, 2019 of CHF 31.5 million providing runway through 2021
  • Awarded Eurostars / Innosuisse grant of €4.85 million supporting mGlu7 NAM PTSD program
  • Additional funding of $1.6 million in 2019 from Indivior to support GABAB PAM addiction program
  • Dipraglurant pivotal registration study in PD-LID ready to start dosing patients subject to lifting of restrictions in US associated with the global Covid-19 crisis

Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported its full-year audited results for the year ended December 31, 2019 and provided a corporate update.

“We made significant progress in 2019 in advancing our pipeline of innovative in-house discovered allosteric modulators, including our priority dipraglurant levodopa-induced dyskinesia program, which is ready to start dosing patients in a pivotal registration clinical trial as soon as the Covid-19 crisis is over,” said Tim Dyer, CEO of Addex. “We also achieved important milestones in our GABAB PAM collaboration with Indivior and secured funding from Eurostars/Innosuisse to advance our mGlu7NAM program for PTSD as well as completing the listing of American Depositary Shares (ADSs) on the Nasdaq Stock Market.”

Read the full media release